Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023 09:15 ET
|
Orchestra BioMed Holdings, Inc.
Completed business combination and listing on Nasdaq generating gross proceeds of approximately $70 millionBackBeat CNT™ global pivotal study in hypertensive pacemaker patients on track for initiation...
Orchestra BioMed to Present at Upcoming Investor Conferences
March 07, 2023 08:00 ET
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023
February 24, 2023 08:00 ET
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Strengthens Senior Leadership Team
February 07, 2023 08:00 ET
|
Orchestra BioMed Holdings, Inc.
Avi Fischer, M.D., joins as SVP, Medical Affairs and Innovation; J.C. Simeon assumes role of SVP, Quality George Papandreou, Ph.D., promoted to General Manager and SVP, Focal Therapies; Kunal Faldu...
Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model
January 27, 2023 08:00 ET
|
Orchestra BioMed, Inc.
Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments, LP, completed on January 26, 2023 The...